John Sourbeer
Stock Analyst at UBS
(0.46)
# 3,868
Out of 4,829 analysts
37
Total ratings
26.32%
Success rate
-28.05%
Average return
Main Sectors:
Stocks Rated by John Sourbeer
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CYRX Cryoport | Maintains: Buy | $10 → $11 | $7.16 | +53.63% | 6 | Apr 1, 2025 | |
| STVN Stevanato Group | Maintains: Neutral | $24 → $24 | $23.64 | -0.59% | 2 | Mar 7, 2025 | |
| QDEL QuidelOrtho | Maintains: Neutral | $43 → $45 | $37.50 | +20.00% | 3 | Feb 13, 2025 | |
| QGEN Qiagen | Maintains: Neutral | $50 → $48 | $42.63 | +12.60% | 4 | Feb 7, 2025 | |
| WST West Pharmaceutical Services | Upgrades: Buy | $350 → $390 | $218.17 | +78.76% | 3 | Dec 12, 2024 | |
| PACB Pacific Biosciences of California | Downgrades: Neutral | $2 | $1.11 | +80.18% | 3 | Nov 11, 2024 | |
| ILMN Illumina | Maintains: Neutral | $133 → $145 | $81.20 | +78.57% | 3 | Nov 5, 2024 | |
| MEDP Medpace Holdings | Maintains: Buy | $452 → $480 | $313.91 | +52.91% | 4 | Mar 8, 2024 | |
| AKYA Akoya Biosciences | Maintains: Buy | $7 → $7.5 | $1.16 | +546.55% | 2 | Mar 5, 2024 | |
| BRKR Bruker | Maintains: Buy | $94 → $102 | $40.08 | +154.49% | 3 | Mar 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $50 | $9.46 | +428.54% | 1 | Feb 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $270 | $141.22 | +91.19% | 1 | Sep 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $142 → $128 | $131.85 | -2.92% | 2 | Jul 27, 2022 |
Cryoport
Apr 1, 2025
Maintains: Buy
Price Target: $10 → $11
Current: $7.16
Upside: +53.63%
Stevanato Group
Mar 7, 2025
Maintains: Neutral
Price Target: $24 → $24
Current: $23.64
Upside: -0.59%
QuidelOrtho
Feb 13, 2025
Maintains: Neutral
Price Target: $43 → $45
Current: $37.50
Upside: +20.00%
Qiagen
Feb 7, 2025
Maintains: Neutral
Price Target: $50 → $48
Current: $42.63
Upside: +12.60%
West Pharmaceutical Services
Dec 12, 2024
Upgrades: Buy
Price Target: $350 → $390
Current: $218.17
Upside: +78.76%
Pacific Biosciences of California
Nov 11, 2024
Downgrades: Neutral
Price Target: $2
Current: $1.11
Upside: +80.18%
Illumina
Nov 5, 2024
Maintains: Neutral
Price Target: $133 → $145
Current: $81.20
Upside: +78.57%
Medpace Holdings
Mar 8, 2024
Maintains: Buy
Price Target: $452 → $480
Current: $313.91
Upside: +52.91%
Akoya Biosciences
Mar 5, 2024
Maintains: Buy
Price Target: $7 → $7.5
Current: $1.16
Upside: +546.55%
Bruker
Mar 1, 2024
Maintains: Buy
Price Target: $94 → $102
Current: $40.08
Upside: +154.49%
Feb 2, 2023
Initiates: Neutral
Price Target: $50
Current: $9.46
Upside: +428.54%
Sep 7, 2022
Initiates: Buy
Price Target: $270
Current: $141.22
Upside: +91.19%
Jul 27, 2022
Maintains: Buy
Price Target: $142 → $128
Current: $131.85
Upside: -2.92%